The present invention is directed to carboxylic acid-containing pharmaceutical compounds where the carboxylic acid moieties have been substituted with cycloalkyl-dione derivatives, as well as tautomers and pharmaceutically acceptable salt forms thereof. These bioisosteric replacements improve the compound's ability to effectively cross the blood brain barrier and result in improved pharmacokinetic, toxicological, and/or safety profiles.
本发明涉及含有
羧酸的药物化合物,其中
羧酸基团已被
环烷二
酮衍
生物取代,以及它们的互变异构体和药学上可接受的盐形式。这些
生物同位素替代物提高了化合物有效穿过血脑屏障的能力,并导致改善的药代动力学、毒理学和/或安全性能。